Nutraceutical contract manufacturer Bloomios engaged for new range
The hemp and nutraceutical manufacturer specialising in full-service product development, R&D and compliance solutions, has been engaged by several CBD, nootropic and nutraceuticals brands to develop and produce a new range of private-label consumer health and wellness products
Bloomios, a hemp and nutraceutical manufacturer specialising in full-service product development, R&D and compliance solutions, has been engaged by several CBD, nootropic and nutraceuticals brands to develop and produce a new range of private-label consumer health and wellness products.
Bloomios' new products utilise natural ingredients that help promote focus, sleep and relaxation.
The products will be formulated with natural supplements including ashwagandha, melatonin, kratom, lion's mane, valerian root, reishi mushroom designed to help promote focus, sleep and relaxation, as well as address pain and inflammation. Several of the products are already in the late stages of development and production testing.
The new offerings represent a significant expansion from the company's existing lines of hemp-derived and nutraceutical products which already provide its private- and white-label customers more than 80 customisable solutions across seven format categories, including the increasingly popular gummy format.
As a long-established contract manufacturer for many well-known cannabinoid brands, Bloomios has been actively supporting these brands' extension into new nutraceutical product lines. This has included the development of proprietary formulations that combine cannabinoids with other compounds or herbal remedies.
"Today's consumers have become increasingly aware of the health benefits that can be derived from a variety of natural supplements and particularly through the combination of complementary ingredients that can create an enhanced entourage effect," noted Bloomios CEO, Michael Hill. "To address the growing demand for such products that require specialised knowledge and production capabilities, major brands have come to us as a single source solution for a new range of natural offerings."
Bloomios' in-house R&D team closely collaborates with its brand partners to rapidly develop new product formulations that align with current consumer preferences including the most popular delivery formats. Together they recently created several novel gummy formulations, including melatonin, valerian root complex and cannabinoids for sleep; L-theanine and CBD for calm; and ginkgo biloba, caffeine and rhodiola rosea for mental focus.
Other health and wellness supplements Bloomios now offers on a white label or customised-formula basis include ashwagandha and mushroom nootropics utilising lions mane and reishi varietals.
"One of the hottest trends in the supplement space today is kratom, which is derived from a tree native to Southeast Asia," said Hill. "It contains several chemicals that interact with opioid receptors and is being used to address pain or moderate opioid withdrawal symptoms."
Kratom is currently being evaluated by the NIH's National Institute on Drug Abuse (NIDA), the leading federal agency for scientific research on drug use. NIDA has recognised that people are using kratom to manage drug withdrawal symptoms and cravings related to opioid use, as well as to address pain, fatigue and mental health issues.
Bloomios remains consistent with its commitment to quality, purity and manufacturing best practices, including sourcing only well-established and verified full chain-of-custody kratom extract suppliers and utilising stringent certificate of analysis protocols.
All of Bloomios' cannabinoid, nutraceutical and nootropic products are manufactured by its state- and federal-compliant cGMP facilities. Its state-of-the-art research and manufacturing facilities ensure robust chain-of-custody validation and batch record retention, with an in-house lab providing real-time quality assurance for all ingredients and finished products.
